Press Releases

Shanghai, China, June 19, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its signing of the Science Based Targets initiative’s (SBTi) commitment letter, making it leading biologics CRDMO company to join the SBTi with concrete actions in combating climate changes.

The SBTi is a collaboration between CDP, the World Resources Institute, the UN Global Compact, and Worldwide Fund for Nature to clearly define and promote the development of science-based targets for carbon emission reductions.

In accordance with SBTi criteria and recommendations, WuXi Biologics will develop its near-term science-based emission reduction targets and long-term targets to reach net-zero greenhouse gas (GHG) emissions by 2050. WuXi Biologics’ targets will be in alignment with the SBTi as well as the Paris Agreement, which pursues efforts to limit global warming to 1.5°C above pre-industrial levels.

Dr. Chris Chen, WuXi Biologics’ CEO and ESG Committee Chairman, commented, “To tackle climate challenges, we as a global leading CRDMO have adopted vigorous measures, including formulating climate change policies and establishing a dedicated carbon taskforce, to embed energy conservation and carbon reduction into our global business operations. In addition, we have been improving the disclosure transparency of climate related governance, strategies, risks and performance. Committing to the SBTi is an important component of WuXi Biologics’ carbon strategy, and also marks a new starting point of our carbon action journey. Going forward, we will actively develop science-based carbon targets and emission reduction action plans in accordance with SBTi, and continuously increase our efforts to Net-Zero while advancing global sustainability.”

The company has already begun implementing energy saving projects and exploring more renewable energy use. Its Dundalk site in Ireland receives 100% of its electricity supply from renewable sources, while rooftop photovoltaics have been put into operation in China at its Mashan site in Wuxi city and its Fengxian site in Shanghai. To further promote energy conservation and emission reduction at global sites, the company is to release its Energy Saving White Paper, advocating sustainable development and contributing to the achievement of its carbon reduction target. It has achieved a 27% decrease of GHG emission (scope 1 and scope 2) from 2020 to 2022, contributing significantly to its goal of achieving a 50% decrease in GHG emission intensity by 2030.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media

PR@wuxibiologics.com

Business

info@wuxibiologics.com